GLP-1 Research
Injecting Ozempic into muscle instead of subcutaneous fat alters the drug's absorption rate and increases the risk of…
A 2025 meta-analysis reveals that roughly 25% of weight lost on semaglutide and tirzepatide comes from lean mass…
Ozempic's active ingredient semaglutide is a GLP-1 receptor agonist with robust clinical evidence behind it — here's exactly…
Up to 45% of semaglutide-driven weight loss can come from muscle — here's what the research says about…
New research reveals that tirzepatide produces significant fat loss and body composition improvements, but exercise training alone matches…
Semaglutide is sold under three brand names — Ozempic, Wegovy, and Rybelsus — each with different doses, delivery…
GLP-1 medications can strip 10% of your muscle mass in under a year — here's what the science…
Semaglutide is sold under three brand names — Ozempic, Wegovy, and Rybelsus — and understanding the clinical differences…
New research from SURMOUNT-1 and multiple meta-analyses reveals exactly what tirzepatide does to fat mass, lean mass, and…
Tirzepatide's dual GLP-1 and GIP receptor mechanism is producing weight losses of 15–25% in clinical trials — here's…